\n \n 5 June 2020\n \n
\n\n \n\n \n \n \nThe University of Oxford in partnership with AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford\u2019s COVID-19 vaccine, following landmark agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII).
\n \n\n\n \n 4 June 2020\n \n
\n\n \n\n \n \n \nOn 2 June, the Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials conducted by Oxford University and supported by AstraZeneca, considering 2,000 volunteers to be tested in the country.
\n \n\n\n \n 3 June 2020\n \n
\n\n \n\n \n \n \nOn April 30, the University of Oxford and AstraZeneca announced an agreement for the global development and distribution of the University\u2019s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2. A Phase I/II clinical trial of the Oxford vaccine began in April in the UK to assess safety and immune response in over 1,000 healthy volunteers aged 18 to 55 years across several trial centres in southern England. As the vaccine trials move to Phase III, a larger population is being enrolled consisting of 10,000 participants in the UK with AstraZeneca enrolling 30,000 particpants in the US. On 2 June, the Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials conducted by Oxford University and supported by AstraZeneca, considering 2,000 volunteers to be tested in the country.
\n \n\n\n \n 2 June 2020\n \n
\n\n \n\n \n \n \nOn 13 May Professor Sarah Gilbert gave a short talk and participated in an informal discussion with ambassadors of the United Nations member states, hosted by the UK mission. Here is a summary of her talk.
\n \n\n\n \n 22 May 2020\n \n
\n\n \n\n \n \n \nUniversity of Oxford researchers have begun recruiting for the next phase in human trials of a COVID-19 vaccine in human volunteers. The phase I trial in healthy adult volunteers began in April. More than 1,000 immunisations have been completed and follow-up is currently ongoing. \r\nThe next study will enrol up to 10,260 adults and children and will involve a number of partner institutions across the country.
\n \n\n\n \n 22 May 2020\n \n
\n\n \n\n \n \n \nThe purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers. This study aims to assess how well people across a broad range of ages could be protected from COVID-19 with this new vaccine called ChAdOx1 nCoV-19. It will also provide valuable information on safety aspects of the vaccine and its ability to generate good immune responses against the virus. Follow the title link to learn more.
\n \n\n\n \n 21 May 2020\n \n
\n\n \n\n \n \n \nAstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford\u2019s vaccine widely accessible around the world in an equitable manner. AstraZeneca today received support of more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of the vaccine, starting in the fall. The development programme includes a Phase III clinical trial with 30,000 participants and a paediatric trial.
\n \n\n\n \n 19 May 2020\n \n
\n\n \n\n \n \n \nWe are writing in response to the article published on Forbes online on 16th May by William Haseltine relating to the BioRxiv preprint publication \u2018ChAdOx1 nCoV-19 vaccination prevents SARSCoV-2 pneumonia in rhesus macaques' by van Doremalen et al (2020).
\n \n\n\n \n 18 May 2020\n \n
\n\n \n\n \n \n \nThe Government has announced \u00a365.5 million of new funding for the vaccine being developed at the University of Oxford as coronavirus vaccine trials accelerate.
\n \n\n\n \n 30 April 2020\n \n
\n\n \n\n \n \n \nA team from the Medical Sciences Division led by Dr Anita Milicic at the Jenner Institute has received a share of $14 million in funding from the Chan Zuckerberg Initiative as one of 29 projects that will explore emerging ideas regarding the role of inflammation in disease.
\n \n\n\n \n 30 April 2020\n \n
\n\n \n\n \n \n \nThe University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University. The vaccine candidate was developed by the University\u2019s Jenner Institute who began trials in humans last week jointly with the University\u2019s Oxford Vaccine Group.
\n \n\n\n \n 16 April 2020\n \n
\n\n \n\n \n \n \nMilliporeSigma (also known as Merck KGaA, and distinct from the pharmaceutical company Merck & Co Inc / MSD) and the Jenner Institute today announced that the Jenner Institute has laid the foundation for large-scale production of its Covid-19 vaccine candidate, ChAdOx1 nCoV-19. With patients enrolled for clinical trials for this vaccine, rapid development of the large-scale manufacturing process is a critical step in quickly and safely delivering it from the lab to patients.
\n \n\n\n \n 2 April 2020\n \n
\n\n \n\n \n \n \nVaccine development during an epidemic: Experts have estimated that it will take 12-18 months to develop a new vaccine at high speed. Under normal circumstances, most vaccine development programmes take more than five years, so this is still a considerably accelerated timescale.
\n \n\n\n \n 27 March 2020\n \n
\n\n \n\n \n \n \nUniversity of Oxford researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) today for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won\u2019t be ready for some weeks still. The team will enrol healthy volunteers aged between 18 \u2013 55, who, if they pass screening, will be the first humans to test the new vaccine, called ChAdOx1 nCoV-19.
\n \n\n\n \n 25 March 2020\n \n
\n\n \n\n \n \n \nDuring the developing COVID-19 pandemic, the Jenner Institute is taking measures to prevent the spread of the disease. Departments are instructed by the University\u2019s Registrar to work from home and manage building closures. This is to restrict any contact between individuals as far as possible. The University remains open and operating as far as possible with the following restrictions: Only essential activities should continue on site (e.g. research relating to Covid-19 or that of national importance, or the maintenance of research equipment and animal welfare). Departments are responsible for defining what is essential, in line with divisional guidance, and should provide appropriate operating procedures. The Pro-Vice Chancellor for Research will be in touch with Divisions to assist in drawing up guidance. Other research and teaching continues remotely where possible and students return home (if possible and where that has not already happened). Departments physically close except where essential activities have to be done on site. Staff work remotely where possible. Only core support functions and other essential activities continue on site and only with critical staff on site, e.g. building access and maintenance security, animal welfare, maintenance of research equipment.
\n \n\n\n \n 20 March 2020\n \n
\n\n \n\n \n \n \nResearchers at Oxford University are working with great care, and due haste, in developing a new vaccine for coronavirus. Production is underway and trials could start in late Spring. If proven effective, a safe coronavirus vaccine could provide an exit strategy for the pandemic and save lives. While we understand the interest, we ask that the media do not continue to contact researchers while this critical work is underway so that they can focus on these efforts. We will issue press releases in due course.
\n \n\n\n \n 18 March 2020\n \n
\n\n \n\n \n \n \nScientists around the world are working hard to develop a vaccine to prevent COVID-19, but there is a lot to be done. A team from the Jenner Institute and Oxford Vaccine Group, led by Prof. Sarah Gilbert, Prof. Andrew Pollard, Prof. Teresa Lambe, Dr Sandy Douglas and Prof. Adrian Hill, started work designing a vaccine on Saturday 10th January 2020. The current status is that they have identified a vaccine candidate and are working towards the first clinical testing phase.
\n \n\n\n \n 11 February 2020\n \n
\n\n \n\n \n \n \nOn 30th January 2020 the World Health Organisation declared the outbreak of novel coronavirus (2019-nCoV) a Public Health Emergency of International Concern. This international global health emergency requires an immediate and coordinated international response. The Nuffield Department of Clinical Medicine is supporting global efforts in tackling nCoV. It is prioritising collaborative projects for front line actions. This site\u2019s primary purpose is to provide signposting to projects.
\n \n\n\n \n 7 February 2020\n \n
\n\n \n\n \n \n \nThe Jenner Institute at the University of Oxford has today agreed a contract with Advent Srl, in Italy to produce the first batch of the novel coronavirus vaccine ChAdOx1 nCoV-19 for clinical testing.
\n \n\n\n \n 3 February 2020\n \n
\n\n \n\n \n \n \n \n \n\n